Brokerages Set CryoPort, Inc. (NASDAQ:CYRX) Price Target at $13.31

CryoPort, Inc. (NASDAQ:CYRX) has received a consensus rating of “Moderate Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $13.3125.

Several equities research analysts recently weighed in on CYRX shares. Wall Street Zen downgraded shares of CryoPort from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings reissued a “sell (d+)” rating on shares of CryoPort in a report on Friday, March 27th. Craig Hallum assumed coverage on shares of CryoPort in a report on Monday, March 30th. They issued a “buy” rating and a $15.00 price target for the company. Finally, Needham & Company LLC upped their price target on shares of CryoPort from $12.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, March 4th.

CryoPort Stock Up 0.8%

CYRX stock opened at $10.68 on Friday. The company has a market capitalization of $532.50 million, a P/E ratio of 8.09 and a beta of 1.68. The company has a 50-day simple moving average of $8.66 and a 200 day simple moving average of $9.30. CryoPort has a fifty-two week low of $5.31 and a fifty-two week high of $11.45.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The company had revenue of $45.45 million during the quarter, compared to analyst estimates of $42.92 million. CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%. Equities analysts anticipate that CryoPort will post -0.73 EPS for the current year.

Insider Buying and Selling at CryoPort

In other CryoPort news, CEO Jerrell Shelton sold 7,918 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $63,344.00. Following the completion of the sale, the chief executive officer directly owned 1,054,501 shares of the company’s stock, valued at approximately $8,436,008. This represents a 0.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mark W. Sawicki sold 3,235 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $8.00, for a total transaction of $25,880.00. Following the completion of the sale, the insider directly owned 103,697 shares of the company’s stock, valued at $829,576. The trade was a 3.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 59,939 shares of company stock valued at $471,183. 10.10% of the stock is owned by insiders.

Institutional Trading of CryoPort

Several institutional investors and hedge funds have recently bought and sold shares of CYRX. AQR Capital Management LLC raised its holdings in CryoPort by 285.5% during the 1st quarter. AQR Capital Management LLC now owns 262,596 shares of the company’s stock worth $1,597,000 after buying an additional 194,482 shares during the period. Creative Planning acquired a new stake in CryoPort during the 2nd quarter worth about $96,000. Rhumbline Advisers raised its holdings in CryoPort by 17.6% during the 2nd quarter. Rhumbline Advisers now owns 92,098 shares of the company’s stock worth $687,000 after buying an additional 13,778 shares during the period. American Century Companies Inc. raised its holdings in CryoPort by 24.4% during the 2nd quarter. American Century Companies Inc. now owns 88,876 shares of the company’s stock worth $663,000 after buying an additional 17,459 shares during the period. Finally, Prudential Financial Inc. acquired a new stake in CryoPort during the 2nd quarter worth about $254,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.